Emerging pharmacotherapy for inflammatory bowel diseases

Hua Luo, Guiqing Cao, Chun Luo, Dechao Tan, Chi Teng Vong, Yinyue Xu, Sicen Wang, Haitao Lu*, Yitao Wang*, Wanghui Jing*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

38 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) refers to a gamut of disorders that are characterized by chronic intestinal inflammation, including ulcerative colitis (UC) and Crohn's disease (CD), which often leads to mucosal ulceration and progressive loss of intestinal function. The etiopathogenesis of IBD has not been completely clarified, although multiple factors involving genetic modifications, host immune dysfunction, intestinal dysbiosis and environmental effects have been implicated. Currently, pharmacotherapies including both non-targeted and targeted biological agents are widely used for the clinical treatment of IBD. In addition, novel therapeutic approaches that target the intestinal microorganisms, such as fecal microbiota transplantation, antibiotics, probiotics and microbial metabolite inhibitors, are also under development. However, these treatments are either accompanied by side effects or cannot achieve complete clinical remission when used alone. The efficacy and safety of drugs are currently a clinical challenge. Thus, advanced drug delivery systems are needed for targeted delivery of drugs to the inflammatory sites and avoid absorption by healthy tissues. In this review, we have summarized the latest research on the pathogenesis of IBD and the emerging pharmacotherapies, and discussed potential therapeutic targets for innovative therapies.

Original languageEnglish
Article number106146
JournalPharmacological Research
Volume178
Early online date25 Feb 2022
DOIs
Publication statusPublished - Apr 2022

Scopus Subject Areas

  • Pharmacology

User-Defined Keywords

  • Emerging pharmacotherapy
  • IBD
  • Molecular pathogenesis
  • Therapeutic targets

Fingerprint

Dive into the research topics of 'Emerging pharmacotherapy for inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this